ReviewDigestive diseases and sciences2012
Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation.
Review in Digestive diseases and sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 89 citations in OpenAlex.
- Autoantibodies in the follow-up of autoimmune hepatitis.Journal of translational autoimmunity · 2026Review
- Development of a Chimeric Protein BiPPB-mIFNγ-tTβRII for Improving the Anti-Fibrotic Activity in Vivo by Targeting Fibrotic Liver and Dual Inhibiting the TGF-β1/Smad Signaling Pathway.The protein journal · 2023Article
- Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis.Transplant international : official journal of the European Society for Organ Transplantation · 2022Article
- Current status of glucocorticoid usage in solid organ transplantation.World journal of transplantation · 2021Review
- Single-Center North American Experience of Liver Transplantation in Autoimmune Hepatitis: Infrequent Indication but Good Outcomes for Patients.Journal of the Canadian Association of Gastroenterology · 2021Article
- The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis.Hepatology international · 2021Article
- Approach to the patient with acute severe autoimmune hepatitis.JHEP reports : innovation in hepatology · 2020Review
- Myth: Liver Transplant Provides a Cure for Liver Disease.Clinical liver disease · 2019Review
- Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies.Journal of immunology research · 2019Review
- De Novo Autoimmune Hepatitis After Living Donor Liver Transplantation: A Series of 4 Cases.Journal of clinical and experimental hepatology · 2018Article
- RethinkingWorld journal of gastroenterology · 2018Review
- Autoimmune Hepatitis in the Liver Transplant Graft.Clinics in liver disease · 2017Review
- Lack of Clinical Relevance of ANA and ASMA Positivity in Patients with Liver Transplantation without a History of Autoimmune Diseases.BioMed research international · 2017Article
- De novo autoimmune hepatitis in liver transplant: State-of-the-art review.World journal of gastroenterology · 2016Review
- Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions.Gut and liver · 2016Review
- Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research.Transplantation · 2016Review
- [De novo autoimmune hepatitis after liver transplantation].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016Article
- Management of Difficult Cases of Autoimmune Hepatitis.Current gastroenterology reports · 2016Review
- Gender and ethnic differences in the post-liver transplant outcomes of patients with autoimmune hepatitis with acute liver failure at initial presentation: a case-control study.Archives of medical science : AMS · 2015Article
- Autoimmune hepatitis.Frontiers of medicine · 2015Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hepatitis can recur or appear de novo after liver transplantation, and it can result in hepatic fibrosis, graft loss, and re-transplantation. The goals of this review are to describe the prevalence, manifestations, putative pathogenic mechanisms, outcomes, and management of these occurrences. Autoimmune hepatitis recurs in 8-12 % of transplanted patients at 1 year and 36-68 % at 5 years. Recurrence may be asymptomatic and detected only by surveillance liver test abnormalities or protocol liver tissue examination. Autoantibodies that characterized the original disease, hypergammaglobulinemia, increased serum immunoglobulin G level, and histological findings of interface hepatitis, lymphoplasmacytic infiltration, perivenular hepatocyte necrosis, pseudo-rosetting, and acidophil bodies typify recurrence. Premature corticosteroid withdrawal and pre-transplant severity of the original disease are possible risk factors. De novo autoimmune hepatitis occurs in 1-7 % of patients 0.1-9 years after transplantation, especially in children. The appearance of autoantibodies may herald its emergence, and antibodies to glutathione-S-transferase T1 have been predictive of the disease. Recurrent disease may reflect recruitment of residual memory T lymphocytes and host-specific genetic predispositions, whereas de novo disease may reflect an allo-antigenic immune response and molecular mimicries that override self-tolerance. Treatment should be appropriate for autoimmune hepatitis and not based on anti-rejection drugs. Corticosteroid therapy alone or combined with azathioprine is the essential treatment. The substitution of mycophenolate mofetil for azathioprine and switch of the calcineurin inhibitor or its replacement with rapamycin have also been used for refractory disease. Re-transplantation has been necessary in 8-23 %.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.